Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burns, Tracy
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA	Terminated	2	8	Europe, US, RoW	Itraconazole Powder, PUR1900, Placebo	Pulmatrix Inc., Pulmatrix, Inc.	ABPA	02/24	02/24
Sweeny, Lisa
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA	Terminated	2	8	Europe, US, RoW	Itraconazole Powder, PUR1900, Placebo	Pulmatrix Inc., Pulmatrix, Inc.	ABPA	02/24	02/24
Jannsen, Nicolaas
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA	Terminated	2	8	Europe, US, RoW	Itraconazole Powder, PUR1900, Placebo	Pulmatrix Inc., Pulmatrix, Inc.	ABPA	02/24	02/24
Catterall, Diane
NCT05667662 / 2022-002289-33: Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA	Terminated	2	8	Europe, US, RoW	Itraconazole Powder, PUR1900, Placebo	Pulmatrix Inc., Pulmatrix, Inc.	ABPA	02/24	02/24
NCT05537025: Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis Oct 2023 - Dec 2023 : Data from trial for IPF	Recruiting	1/2	97	Europe, RoW	ARO-MMP7 Inhalation Solution, Placebo	Arrowhead Pharmaceuticals	Idiopathic Pulmonary Fibrosis	03/25	03/25